• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Gastrointestinal
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment with Esomeprazole 20 mg qd to Placebo qd in Patients with Heartburn and Sleep Disturbances Associated with Gastroesophageal Reflux Disease (GERD)

Disease
gastrointestinal diseases
Drug Name
Nexium
Generic Name
esomeprazole
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IV
Start Date
Apr 10, 2008
Study Name
D9612L00122
Study Id
D9612L00122
ClinicalTrials.gov ID
NCT00660660
Recruiting Status
Closed
Protocol Status
Not Available
Report
Jan 18, 1971
  • D9612L00122.pdf (182 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013